key: cord-0012797-23oqoqln authors: Yang, Fan; Shi, Kun; Jia, Yan-peng; Hao, Ying; Peng, Jin-rong; Qian, Zhi-yong title: Advanced biomaterials for cancer immunotherapy date: 2020-03-02 journal: Acta Pharmacol Sin DOI: 10.1038/s41401-020-0372-z sha: 4d3137fb7a37606ff5f840648db514295c30d009 doc_id: 12797 cord_uid: 23oqoqln Immunotherapy, as a powerful strategy for cancer treatment, has achieved tremendous efficacy in clinical trials. Despite these advancements, there is much to do in terms of enhancing therapeutic benefits and decreasing the side effects of cancer immunotherapy. Advanced nanobiomaterials, including liposomes, polymers, and silica, play a vital role in the codelivery of drugs and immunomodulators. These nanobiomaterial-based delivery systems could effectively promote antitumor immune responses and simultaneously reduce toxic adverse effects. Furthermore, nanobiomaterials may also combine with each other or with traditional drugs via different mechanisms, thus giving rise to more accurate and efficient tumor treatment. Here, an overview of the latest advancement in these nanobiomaterials used for cancer immunotherapy is given, describing outstanding systems, including lipid-based nanoparticles, polymer-based scaffolds or micelles, inorganic nanosystems, and others. Cancer immunotherapy is a promising treatment for cancer that aims to provide treatment more accurately and safely than other traditional therapies [1, 2] . Agents are designed to provoke a robust primary and secondary antitumor immune response by repairing or enhancing natural mechanisms that are evaded or damaged during disease progression, thus inhibiting tumor growth and metastasis [3] [4] [5] . Approximately a century ago, Coley first used a method to activate the patient's immune system to help treat tumors [6] . In the immune system, antigen-presenting cells (APCs) continuously eliminate exogenous or endogenous antigens; antigens are taken up and processed to be exposed onto major histocompatibility complexes (MHCs) I or II on the APC surface for further presentation to naive T cells [7, 8] . The three main pathways by which APCs activate T cells are the binding of MHC complexes to T-cell receptors, the presence of costimulatory molecules on the cell surface (CD80 and 86 on APCs binding to CD28 on T cells) and the cytokines that stimulate T cells [9] . T cells can differentiate into two major subpopulations: CD4 + T cells, which can further differentiate into T-helper 1 (Th1) and T-helper 2 (Th2) cells, and CD8 + T cells, which can further differentiate into cytotoxic T lymphocytes (CTLs) to directly kill tumor cells [9, 10] . Both CD8 + T cells and IFN-γ-secreting Th1 CD4 + T cells play a vital role in killing tumors [10, 11] (Fig. 1) . In 1986, the US Food and Drug Administration (FDA) approved recombinant versions of the cytokine interferon-α (IFN-α) as the first cancer immunotherapeutic drug for the treatment of hairy cell leukemia; however, IFN-α was replaced because of its short therapeutic duration [12] . Subsequently, recombinant interleukin-2 (IL-2) was approved by the FDA as a cancer immunotherapy drug for the treatment of metastatic renal cancer (in 1992) and metastatic melanoma (in 1998), separately [13] . Although IL-2 initially has a good therapeutic effect in some patients, the use of large doses due to its short half-life results in many immunerelated side effects, such as cytokine release syndrome and vascular leakage syndrome [14] [15] [16] . After a stagnant phase, sipuleucel-T (an autologous dendritic cell (DC) therapy) as the first cancer therapeutic vaccine was approved by the FDA for prostate cancer, which meant tumor immunotherapy had finally made successful progress in the early 21st century. However, production complexities and other issues hindered the clinical translation of sipuleucel-T [17, 18] . Since the cytotoxic T-lymphocyte antigen-4 (CTLA-4)-targeted checkpoint inhibitor ipilimumab was approved for advanced melanoma in 2011 [19] , there has been a shift towards novel immunotherapies, including programmed cell death-1 or its ligand monoclonal antibody (aPD1 or aPDL1) [20] and chimeric antigen receptor (CAR) T-cell therapies [21] [22] [23] . Although these treatments have been developed and approved for clinical use and have achieved some efficacy, many problems regarding safety and effectiveness remain to be solved [14, 24, 25] . In terms of safety, some immunotherapeutic drugs require a large dose for their short half-life, which causes autoimmune side effects in some patients. For example, two syndromes (cytokine release syndrome and vascular leakage syndrome) caused by IL-2 lead to severe and even lethal systemic inflammatory reactions in some patients [25] . In terms of efficacy, current immunotherapy is only effective in some patients, and most immunotherapy is initially used only to treat hematological tumors. Only a few immunotherapies for the treatment of solid tumors are approved because solid tumors have a complex tumor microenvironment (TME) that is a difficult barrier to break through [26] . To reduce side effects and improve the accuracy of immunotherapy, novel delivery systems need to be manufactured. In recent years, with the development of nanotechnology, an increasing number of delivery systems have been designed for the local and sustained release of immunotherapeutic drugs in vivo [27] [28] [29] . Biomaterial-based delivery systems have many advantages in cancer immunotherapy, such as the specific and targeted delivery of biomolecules, high efficacy, low toxicity, and immunestimulating effects (Table 1) [27, 30, 31] . A great variety of advanced biomaterials can be used for cancer immunotherapy, including liposomes, polymers, silica, and so on (Fig. 2) [2, 32, 33] . Different biomaterials use various means and technologies to play an important role in cancer prevention [34] [35] [36] [37] [38] . To achieve precise antitumor effects, these advanced biomaterials with different functions can be used to deliver immunopharmaceuticals to organs or tissues (such as the mucosa or skin) that are rich in immune cells by different routes of administration (for instance, intranasally [39] , orally [40] , and subcutaneously [41] ). In this review, we first summarize several major immunotherapeutic strategies and discuss their strengths and weaknesses. We then describe a range of advanced nanobiomaterials that have been used for tumor immunotherapy to enhance efficacy and/or reduce side effects and evaluate the clinical or preclinical impact of these strategies. This article mainly focuses on advanced biomaterials for the following four categories: cytokines, immunological checkpoint inhibitors, engineered T cells, and cancer vaccines. In this section, we outline the four immunotherapies and analyze the options that can be used to address their shortcomings. As recombinant IFN-α was approved for the treatment of hairy cell leukemia, cytokines were the first class of immunotherapy for clinical use [12] . After cytokines are injected into the body, immune cells can be directly activated to generate an immune response. The current cytokines used in immunotherapy mainly include interferon, interleukin, and granulocyte macrophage colony-stimulating factor (GM-CSF) [14] . Usually, when the body is infected by pathogenic microorganisms, interferon is produced to induce the activation and maturation of macrophages, lymphocytes, DCs, and other immune cells [42] . In addition, interferon can also inhibit angiogenesis at the tumor site [43] . Interleukins promote the activation and differentiation of CD4 + T cells, CD8 + cells, and B cells to promote innate and adaptive immune responses [44] [45] [46] . GM-CSF is a cytokine that promotes the differentiation of bone marrow cells; it plays a key role in the activation of DCs and the priming of antitumor CTLs [47] . Both granulocyte colony-stimulating factor (G-CSF) and GM-CSF were approved for use in neutropenia [48] . Although cytokines have a certain effect, due to the short half-life of cytokines, large doses are needed to achieve better therapeutic effects, thus leading to cytokine release syndrome [14] . In addition, cytokines may promote regulatory T-cell growth while inducing stimulated Tcell death, which leads to the emergence of autoimmune diseases [24] . Researchers are currently trying to combine several cytokines or combine cytokines with chemotherapy or other immunotherapies to reduce the dose used and thereby avoid the side effects caused by high doses [43] . Immunological checkpoint inhibitors Immunological checkpoint inhibitors are by far the most studied immunotherapies, and the most commonly used inhibitors are PD-1/PD-L1 (programmed death receptors 1/programmed death receptor-ligand 1) blockade and CTLA-4 inhibition. Immune checkpoints are inhibitory pathways in the immune system that maintain self-tolerance and regulate the physiological immune balance [49] . Activated T cells express PD-1 to recognize and remove abnormal or cancerous cells [50] . However, tumor cells inactivate the T cells that recognize tumor antigens by expressing PD-1 ligands that bind to PD-1, thereby evading immune system attacks [51] . Therefore, tumor cell death can be induced by blocking inhibitors of PD-1 or its ligand. CTLA-4 is another immune checkpoint that reduces T-cell activation and promotes tumor progression by binding to its ligands (CD80 and CD86) [52] . Inhibitors against CTLA-4 and its ligands block their interactions to increase T-cell activity and thereby clear tumors. In the past few years, PD-1, PD-L1, or CTLA-4 checkpoint blockade strategies have achieved encouraging clinical results. More than five checkpoint inhibitors have been approved for different tumors [53] . However, it is disappointing that there are Fig. 1 Scheme of the cancer immunotherapy mechanism. After antigens are processed by immature dendritic cells (ImDCs), they are presented to T cells by mature dendritic cells (mDCs) through major histocompatibility complex (MHC) class I or MHC class II complexes binding to CD8 + or CD4 + T cells, separately. Simultaneously, mDCs also express costimulatory molecules and cytokines such as IFN-γ and IL-12 to synergistically stimulate T cells. CD8 + T cells further differentiate into cytotoxic T lymphocytes (CTLs), and CD4 + T cells further differentiate into IFN-γ secreting T-helper 1 (Th1) cells to assist in activating CD8 cells and other innate immune cells, such as natural killer (NK) cells, granulocytes or macrophages, to directly kill tumor cells many limitations to their use. As described above, the systemic use of immunological checkpoint inhibitors can cause damage to many normal organs [54, 55] . In addition, not all patients can benefit from checkpoint inhibitors, and studies on the reactivity to checkpoint inhibitors are also underway [56, 57] . Furthermore, the immunosuppressive microenvironment of different tumors varies, and new strategies are needed to achieve precise treatment of tumors [58] . With the development of nanotechnology, these limitations may be addressed by using advanced biomaterials to achieve the precise delivery of drugs at the tumor site. great clinical success and received FDA approval. In CAR T-cell therapy, T cells collected from the peripheral blood of a patient are engineered in vitro to express CARs that specifically recognize tumor antigens and then are reinjected into the same patient to recognize and kill tumors; [59] these T cells can maintain activity for a long time in the body [60] . However, CAR T-cell therapy is time-consuming, expensive, and technically demanding, which limits its widespread use [61] . In 2017, two CAR T-cell therapies targeting CD-19 were approved for the treatment of lymphoma [62, 63] . B-cell leukemias and lymphomas highly express CD-19 molecules. Moreover, normal cells expressing CD-19 have only B-cell lineages. Therefore, the main side effect of CAR T cells targeting CD-19 is B-cell hypoplasia, which can be alleviated by immunoglobulin replacement therapy [64] . The clinical success of CD-19 CAR T cells has inspired many studies of CAR T-cell therapy for different antigens or combinations of several antigens [65] [66] [67] . However, CAR T-cell therapy causes cytokine release syndrome and neurotoxicity [68] , and in some cases (especially solid tumors with hash microenvironments), the survival of CAR T cells is affected [69, 70] . Therefore, new biomaterials and techniques are urgently needed to improve the survival of CAR T cells. TCR T cells are clinically available for hematological and solid cancers. TCRs respond to MHC-presented tumor-associated intracellular antigens, such as neoantigens and cancer-testis antigens [71] . TCR T cells are MHC-dependent immunotherapies. In addition, preclinical studies have shown that the specificity of TCR T cells plays an important role in clinical outcomes; [72] however, the toxicity caused by high-affinity TCR T cells is also difficult to predict [73] . For the above reasons, it is particularly important to develop new technologies and new biomaterials to avoid the toxicity of CAR T cells and TCR T cells while improving their applicability to solid tumors. The four main cancer vaccines are DCs, tumor cell lysates (TCLs), nucleic acids, and neoantigens [74] . DC vaccines are a widely studied class of cell-based tumor vaccines in which DCs obtained from patients are stimulated in vitro to express tumor-associated antigens and then directly activate T cells to kill tumors. As mentioned above, one DC vaccine approved for prostate cancer is sipuleucel-T [75] . However, other DC-based vaccines have failed in clinical studies despite their high safety [76] . It is predicted that the therapeutic effect on a tumor can be improved by increasing the expression level of the target antigen on the surface of the DC [77] and promoting the lymph node delivery efficiency of the DC vaccine [78] . Tumor cell lysates can be prepared by two common clinical methods: ultraviolet B ray irradiation or freeze-thaw cycles. Tumor cell lysates contain a variety of tumor-associated antigens, which can avoid ineffective immunization caused by the loss of a single antigen after tumor mutation. In addition, TCLs are suitable for all patients and are not restricted to their HLA type [79] . Clinical experiments have shown that tumor cells can be modified to express more immune-related elements, including interleukins, costimulatory molecules, etc., so that TCLs can produce a stronger antitumor immune response in vivo after injection [74] . However, many TCL-associated vaccines have failed in Phase II or Phase III clinical trials [80] , suggesting that tumor lysate vaccines require new techniques and materials to increase their effectiveness. The nucleic acid vaccine is a promising alternative to traditional vaccines that work by delivering exogenous nucleic acids into target cells [81] . Nucleic acid therapeutic drugs consist of DNAs or RNAs that are taken up and translated into antigenic proteins by APCs, which induce immune responses against the target proteins to kill tumors expressing target antigens [81] . Although DNAbased nucleic acid vaccines have been clinically tested, they have failed due to their intranuclear delivery difficulties and somewhat disappointing immunogenicity [82, 83] . In contrast, RNA-based nucleic acid vaccines can be directly translated into antigenic proteins, which enhance immune efficiency. Furthermore, since RNA is a naturally occurring molecule, its preparation cost is low, and its half-life can be extended by modification. Moreover, RNA is not integrated into the genome as DNA is and therefore does not cause hereditary side effects [84] . However, naked RNA is highly susceptible to degradation by nucleases; therefore, it requires special transfection reagents or delivery techniques to enhance its intracellular delivery [85] . Thus, nucleic acid vaccines can greatly benefit from advanced delivery technologies and materials, which are technical barriers to current nucleic acid vaccines. An effective and safe delivery system is the key to the successful application of nucleic acid vaccines. Neoantigen vaccines use tumor somatic DNA as antigens to promote the antitumor immune response [86] . These antigens are only expressed in tumor cells and can avoid damage to normal tissues [87] . Advanced materials and delivery systems can improve the stability of these neoantigens and combine multiple vaccine classes to improve the safety and efficacy of cancer vaccines [88] [89] [90] . Lipid-based biomaterials As the most powerful professional APCs, DCs have the potency of integrating both innate and adaptive immunity [91] [92] [93] [94] . Antigens must be seized by APCs, especially DCs, to induce a cytotoxic CD8 + T-cell (CTL) immune response directed against tumors (Fig. 3 ) [95] [96] [97] [98] . Since cellular DC vaccines require a timeconsuming and costly preparation process [99, 100] , lipid-based nanobiomaterials such as liposomes have been explored to deliver antigens and adjuvants directly to DCs in vivo [101] [102] [103] . Liposomes. Liposomes are nanosized bubbles made of a phospholipid bilayer [104, 105] , which are the main lipid-based nanobiomaterials. Liposomes have been studied as potential vectors of immunotherapy for many years, including marketed vaccines for influenza (Inflexal ® ), Hepatitis A (Epaxal ® ), and recently, malaria (Mosquirix) for the property of being easily functionalized [106] . Lai et al. synthesized liposomes that were loaded with a melanoma-specific TRP2180-188 peptide and modified with the DC-targeting mannose and immune adjuvant CpG-ODN. These liposomes significantly increase tumor antigen-specific CD8 + cytotoxic T cells, and this leads to the inhibition of tumor angiogenesis and tumor cell proliferation [107] . Le Moignic et al. reported a dramatic mRNA delivery system made with cationic liposomes (L), a cationic polymer (P), and mRNA (R) that promoted DC-targeting and exerted cogent antitumor responses [102] . To increase the environmental responsiveness of liposomes, highly pH-sensitive polymers were modified on the surface of liposomes: they promoted the secretion of Th1 cytokines from DCs and enhanced the therapeutic effects of the tumor [108, 109] . Yuba et al. designed a codelivery system to simultaneously load antigen and IFN-γ genes by using pH-sensitive liposome-loaded antigen and lipoplexes containing the IFN-γ gene, which resulted in strong therapeutic effects [110] . Moreover, combining these pH-sensitive liposomes with DC-targeting adjuvants could trigger double stimulation to DCs and promote antitumor immunity [111] . Advanced biomaterials for cancer immunotherapy F Yang et al. Another study suggested that liposomes that were modified with small molecule inhibitors to prevent TGFβ from binding with the TGFβ receptor and preloaded on T cells could improve the infiltration of T cells into B16F10 melanoma tumors more efficiently [112] . Drugs wrapped by liposomes have a prolonged blood circulation time and reduced adverse effects [113] . In recent years, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4)-blocking monoclonal antibody had been used in clinical research and achieved some effects [114, 115] . However, its adverse effects were also serious [116] . Nikpoor et al. studied the antitumor effects of liposomes containing a CTLA-4 blockade antibody and proved that the PEGylated liposomal formulation of CTLA-4 could improve the antitumor immune response and therefore merited further human tumor-associated studies [117] . To improve the efficiency of antigen delivery, Miura et al. reported liposomes modified with a KALA peptide (WEAKLAKALAKALAKHLAKALAKALKA), an α-helical cationic peptide, and encapsulated antigens that delivered antigens to the cytoplasm and achieved a more antigen-specific cytotoxic T-lymphocyte response [118] . Recently, many studies proved that combined photothermal immunotherapy could potentiate the antitumor immune response and overcome the limitations of photothermal therapy (PTT) [119, 120] . Li et al. illustrated that fluorophore-loaded liposomes (IR-7-lipo) modified with an immunoadjuvant (HA-CpG) could synergistically activate CD8 + T effector cells and alleviate the immunosuppressive TME [121] . Furthermore, researchers prepared liposome-coated gold nanocages containing adjuvant MPLA and melanoma antigen peptide TRP2 and modified them with the DCspecific antibody aCD11c on the surface; they confirmed that these liposomes potentiated the activation and maturation of DCs by the targeting capacity of aCD11c, and the migration of DCs could also be monitored in real time by fluorescence and photoacoustic imaging [122] . tyrosinase-related protein 2 (Trp2) peptide and CpG-ODN; they proved that SUN b-PM could enhance the effects of immunotherapy for advanced melanoma by modulating the TME [126] . Micelles. When the critical micelle concentration was reached, amphiphilic polymers self-assembled as nanosized particles, namely, micelles [127, 128] . Particles with a smaller size and neutral charge may arrive more easily at the draining lymph nodes and enhance systemic spread [90, [129] [130] [131] [132] . To induce systemic toxicity and promote the maturation of DC, Zeng et al. produced an amphiphilic molecule (PSA) by modifying polyethyleneimine (PEI)-2k with stearic acid, and PSA micelles selectively accumulated in the draining lymph nodes rather than the systemic area. Moreover, PSA micelles stimulated the secretion of CCR-7 and the expression of CD86 and MHC-II in draining lymph nodes, and PSA micelles loaded with Trp2 showed significant antitumor effects [133] . Poly(ethylene glycol)-blockpoly(L-arginine)-based micelles delivered to a tumor site via enhanced permeability and retention effects suppress tumor progression by targeting macrophages and promoting the generation of NO in the tumor site [134] . Another tumorassociated macrophage (TAMs)-targeted micelle, galactosefunctionalized zinc protoporphyrin IX (ZnPP)-grafted poly(Llysine)-b-poly(ethylene glycol) polypeptide micelles (ZnPP PM), was reported, and these micelles could repolarize TAMs to M1 macrophages by producing reactive oxygen species (ROS) [135] . A mixed micellar system loaded with curcumin (CUR) was proven to have good bioavailability and to downregulate proinflammatory cytokines, which provided a new idea for surmounting the development of resistance in endometrial cancer [136] . Another CUR-PEG micelle, a curcumin-polyethylene glycol conjugate, was designed to promote antitumor effects combined with a vaccine, and it significantly increased interferon-γ (IFN-γ) production and reduced immunosuppression in the TME [137] . However, a high concentration of IFN-γ may induce systemic toxicity. Ishii et al. designed polyion complex (PIC) micelles whose viscosity was low at room temperature but increased under physiological conditions and proved that this gel loaded with IL-12 could inhibit tumor growth and decrease side effects [138] . Cui et al. investigated polyplex micelles loaded with genes encoding the tumor-associated antigens SART3, GM-CSF, and CD40L and demonstrated that these micelles when administered subcutaneously may be safe and effective for tumor immunotherapy [139] . Researchers manufactured polymeric hybrid micelles (PHMs) loaded with Trp2 and CpG, and these PHMs consisted of polycaprolactone-polyethylene glycol (PCL-PEG) and 10% (w/w) PCL-PEI and were proven to have the ability to deliver antigen and adjuvant to lymph nodes and stimulate the CTL response, thus effectively inhibiting tumor growth [140] . Luo et al. prepared poly(ethylene glycol)-b-poly(L-lysine)-b-poly(L-leucine) (PEG-PLL-PLLeu) micelles coloaded with OVA and STAT3 siRNA and proved that these micelles downregulate the expression of STAT3 and promote the maturation of DCs, thus improving the therapeutic efficacy of tumor vaccines [141] . Moreover, PEG-PLL-PLLeu selfassembled into micelles containing miR-148ai, and OVA reprogrammed the immunosuppression of tumor-associated dendritic cells (TADCs) by inhibiting the DNMT1 gene, which upregulated SOCS1, the suppressor of TLR signaling, and these findings provided a novel idea for antitumor immunotherapy [142] . Li et al. designed carboxylated micelles modified with OVA and toll-like receptor-7 agonist CL264, which showed the ability to deliver antigen and adjuvant to lymph nodes, thus stimulating cellular and humoral antitumor immune responses [143] . Nanoparticles. PLGA copolymers are biodegradable aliphatic polyesters made of diverse proportions of lactic and glycolic acids, which are approved by the FDA to be used in the production of surgical sutures and in some drugs to achieve controlled release [144] [145] [146] [147] . Because its degradation products can be metabolized normally, PLGA has good biocompatibility, and therefore, many researchers use PLGA to deliver not only antitumor agents or drugs such as paclitaxel [148] , 9nitrocamptothecin [149] , and estradiol [150] but also cancer vaccines [151] [152] [153] [154] [155] [156] . Researchers have successfully manufactured PLGA NPs loaded with cancer cytomembranes, which can simultaneously deliver tumor-associated antigens and adjuvants so that these NPs can promote the expression of surface biomarkers on DCs. Moreover, this strategy can be used to target the source of cancer cells by an isotypic combining mechanism and is beneficial to antitumor drug delivery [157] . A PLGA-based biomimetic artificial antigenpresenting cell (aAPC) combined with an anti-PD-1 monoclonal antibody has been proven to have synergistic effects on tumor immunotherapy by motivating cytotoxic CD8 + T cells and decreasing the inhibition of the tumor immunosuppressive microenvironment [158] . PLGA-based NPs that were coloaded with antigens and MPLA can be fractured in the intracellular milieu and promote antigen retention and IFN-γ secretion simultaneously by enveloping the erythrocyte membrane on the surface [159] . PLGA-based microspheres were found to enable the eradication of prostate carcinoma by codelivering tumor lysates, CpG-ODN, and Poly(I:C), and their capacity to stimulate T cells to produce IFNγ and granzyme B was significantly enhanced in TRAMP mice [160] . PLGA polymers were also used to codeliver OVA, CpG-ODN, and Poly(I:C); however, the therapeutic effects were weakened, and the production of IFN-γ and the activation of DCs were decreased under chronic stress [161] . Two TLR7/8 agonists have been synthesized and encapsulated in PLGA NPs. This OVA or tumor lysate NP vaccine significantly inhibits tumor growth in B16F10-OVA or renal cell carcinoma by stimulating the CD8 + CTL response [162] . To realize image-guided delivery of immunomodulators, IFN-γ and iron oxide nanocubes were coencapsulated in PLGA microspheres. This delivery system could provide a convenient way of delivering drugs to tumor sites after injection and monitoring the distribution of drugs sequentially [163] . A new combination method that uses PLGA for encapsulating a physical mixture of ovalbumin and hydroxychloroquine promotes CD8 + CTL and memory T-cell immune responses in tumor tissues via the controlled release of OVA and upregulation of MHC-I and CD86 costimulatory molecules in DCs [164] . To achieve the goal of targeting DCs more accurately, Rosalia et al. designed a PLGAbased CD-40-targeted cancer vaccine that showed significant enhancements in delaying tumor growth and extending the survival of tumor-bearing mice by facilitating antigen-specific antitumor CD8 + T-cell responses [165] . Recently, combination immunotherapy has become a particularly promising strategy for tumor treatment, and PLGA has been used to realize the codelivery of antiprogrammed cell death-1 (aPD1) and T-cell agonist (aOX40) agents to simultaneously rather than sequentially elicit the activation of T cells. These dual-immunotherapy NPs increased the ratio of CD8 + to regulatory T cells infiltrating the tumor, thereby promoting therapeutic efficacy in both B16F10 melanoma tumors and 4T1 breast cancers [166] . Indocyanine green (ICG) and imiquimod (R837) were coloaded by PLGA to achieve the eradication of preexisting tumors and enhance the antitumor immune response simultaneously. Moreover, with the combination of these particles and anti-CTLA-4, this strategy has been proven to delay tumor growth and extend survival in both 4T1 and CT26 tumor models [167] . PLGA polymers as biodegradable materials can also be combined with photothermal agents. Researchers produced anti-PD-1 peptide (AUNP12) and hollow gold nanoshell coencapsulated PLGA NPs, and these particles facilitated the effective inhibition of primary Advanced biomaterials for cancer immunotherapy F Yang et al. and distal tumor growth via an increasing percentage of CD8 + CTLs and secretion of IFN-γ [168] . In addition, the coadministration of anti-PD-1 peptide (AUNP12) and hollow gold nanoshell coencapsulated PLGA NPs with CpG has been proven to mediate the maturation of DCs in vitro and enable direct tumor necrosis in bilateral and lung metastatic 4T1 tumor-bearing mice [169] . The antibody-modified PLGA core was used to load the hydrophobic drug imatinib (IMT), which was developed as an inhibitor of tyrosine kinase and then manufactured as IR-780 and IMT codelivery PH-sensitive NPs, which showed a great capacity to stimulate an effective CD8 + T-cell antitumor immune response [170] . Researchers have compared the capacity of synthetic long peptide-based cationic liposomes and PLGA NPs to induce an immune response. They proved that liposomes have advantages over PLGA particles for inducing the T-cell response. However, the mechanism of this phenomenon has not been investigated [171] . In addition, PLGA polymers used to formulate antigen-capturing nanoparticles (AC-NPs) were proven to promote an antitumor immune response and improve the efficacy of αPD-1 immunotherapy. The surfaces of PLGA NPs were modified by different chemical groups to bind tumor antigens; however, although all other AC-NPs except mPEG AC-NPs loaded plenty of proteins, PLGA and Mal AC-NPs showed a higher ability to improve the immunotherapeutic efficacy (Fig. 4) [172] . Hydrogels. Hydrogels can serve as antigen storage caverns because of their gelation properties, and they have been used as vectors to coload cytokines, proteins, DNAs, and so on [31, [173] [174] [175] [176] [177] [178] [179] . Alginate microparticle-based injectable gels were reported~10 years ago and have been used to codeliver mature DCs and chemokines CCL21 and CCL19. The study showed that this hydrogel system could recruit host DCs to the injection site and migrate to local lymph nodes at the same time, thus providing a continual process to initiate the immune response [180] . Researchers have designed a two-step strategy to realize the recruitment of APCs and presentation of antigens via the injection of GM-CSF delivering mPEG−PLGA hydrogels followed by the administration of antigen-loaded vectors, which showed obvious antitumor immunotherapeutic potential [181] . Nanogel particles formed by cholesteryl pullulan showed the good function of delivering and cross-presenting antigens to medullary macrophages. In addition, the study revealed that this vaccine could significantly slow tumor growth with the help of Toll-like receptor agonists [182] . Hyaluronic acid-tyramine-based hydrogels have been used to deliver IFN-α to the injection site and to inhibit tumor proliferation Reprinted with permission from [172] Advanced biomaterials for cancer immunotherapy F Yang et al. via the coadministration of sorafenib [183] . In addition, a hyaluronic acid-pluronic F-127 hydrogel was used to prepare black phosphorus quantum dot nanovesicles (BPQD-CCNVs), GM-CSF, and LPS coloaded systems. The study showed that the sustained release of GM-CSF and LPS from the injection site could recruit and activate DCs. In addition, NIR irradiation combined with PD-1 antibody could generate a strong antitumor immune response [184] . Mooney and his colleagues manufactured an infectionmimicking system to coload GM-CSF, Toll-like receptor agonists (CpG-ODN) and a tumor lysate to achieve the recruitment and activation of DCs, which promoted a specific and effective antitumor immune response [185, 186] . The same team designed a cryogel-based delivery system to encapsulate GM-CSF and CpG-ODN. This vaccine could be subcutaneously injected into mice and controlled release immunomodulatory factors and cancer antigens, [195] Advanced biomaterials for cancer immunotherapy F Yang et al. thus provoking strong antitumor T-cell responses and improving the survival rate of B16F10-bearing mice [187] . Yang and coworkers reported that hydrogels formed by phosphatase enzymes had good potency in evoking humoral and cellular immune responses and could be used as protein vaccine adjuvants [188] . Moreover, they also proved that peptide Nap-GFFY hydrogels formed by a very simple process could also provoke a cogent CD8 + T-cell immune response [189] . Chao et al. designed a combination system in which ALG was cross-linked by multivalent cations and 131 I-labeled catalase coadministered and jellified in a local tumor site, followed by systemic CTLA-4 injection. This strategy delayed local tumor growth and metastasis [190] . Gu and coworkers designed a therapeutic scaffold formed by a ROS-responsive hydrogel to release gemcitabine (GEM) and an anti-PD-L1 blocking antibody (aPDL1) locally in tumor-bearing mice [191] . This system significantly decreased the level of ROS and the numbers of myeloid-derived suppressor cells and TAMs in the tumor site. Moreover, a 50% survival rate and 30% recurrence rate were observed in the aPDL1-GEM@Gel treatment group on account of primary and memory immune responses. In the same year, this research group also generated another immunotherapeutic gel for postsurgical tumor treatment, which was manufactured by mixing the fibrinogen solution containing anti-CD47 antibody-loaded CaCO 3 NPs and thrombin solution in the postsurgical tumor site [192] . This strategy had the potency of preventing local and distant tumors via activating M1-type TAMs and promoting macrophage phagocytosis and antitumor immune responses. DNA-based supramolecular hydrogels were reported to recruit and activate APCs by releasing a high concentration of CpG, which could serve as a promising method for tumor immunotherapy [193] . Song et al. demonstrated a poly(L-valine) hydrogel for coencapsulating TCL, TLR3 agonist, poly(I:C) that realizes the controlled release of antigens and adjuvants, thus promoting antigen persistence and presentation to enhance the cytotoxic T-lymphocyte immune response against cancer [194] . A tumor-penetrable peptide-based hydrogel was prepared by encapsulating JQ-1 (a BRD4 inhibitor) and ICG coloaded tumor cells (Fig. 5 ) [195] . This vaccine could evoke a strong patientspecific immune response and prevent recurrence and metastasis of postsurgical tumors by NIR laser-triggered release of tumor-specific antigens and JQ-1. Siliceous nanoparticles. Mesoporous silica NPs can be prepared by using organosilane precursors to participate in hydrolysis and condensation reactions [196, 197] . Moreover, the surface of these particles can be modified with various reactive groups for different medical applications [198, 199] . Amino acid-modified silica NPs were reported to promote cytokine production, and silica nanospheres doped with Ca, Mg, and Zn (MS-Ca, MS-Mg, and MS-Zn) showed the capacity to provoke a Th1 anticancer immune response [200, 201] . Both spherical silica NPs and asymmetric mesoporous silica NPs were found to have the potential to activate and mature immune cells [202] [203] [204] [205] [206] . In addition, siliceous NPs also play a strong role in vaccine formulations such as the Japanese encephalitis vaccine [207] , hepatitis B virus DNA vaccine [208] , and oral hepatitis B vaccine [209] , as well as in viral vaccine heat resistance [210] and viral inhibition [211] . Mesoporous silicatemplated and hollow particles were designed to load antigens and adjuvants that showed a robust lymph node targeting and immune cell-activating capacity [212] [213] [214] [215] [216] . Yang et al. achieved the synthesis of dendritic mesoporous organosilica hollow spheres for the first time, which showed a significant potential to provoke an antitumor immune response [217] . Mooney and coworkers reported mesoporous silica rods (MSRs) with a high aspect ratio that spontaneously assembled as a macroporous structure to recruit DCs and generate humoral and cellular immune responses against tumors in the presence of GM-CSF and CpG [218] . They also modified these MSRs with PEG, PEG-RGD, or PEG-RDG groups [219] and PEI (Fig. 6 ) [220] , which promoted immune cell activation and infiltration and may pave the way for cancer vaccination. Iron oxide nanoparticles. Because iron oxide NPs have been approved for human use as MRI contrast agents and their degradation products are good for the body's iron store, iron oxide NPs have been increasingly used simultaneously for cancer immunotherapy and imaging [221] [222] [223] . Iron oxide NPs can be modified with many cargos to improve the antitumor immune response, such as heat shock protein 70 (Hsp70) [224] , R837 and Advanced biomaterials for cancer immunotherapy F Yang et al. Poly(I:C) [225] , CpG-ODN [226] , and ICG [227] . These NPs have the potential to realize the integration of imaging and therapy. Gold nanoparticles. Photothermal immunotherapy is an effective treatment combining laser photophysical effects with immunoregulation [228] [229] [230] . Many photothermal biomaterials, such as gold nanorods [231] , Prussian blue [232, 233] , and NIR photosensitizers [234] , have recently been used for cancer immunotherapy. Gold NP labeled melanoma-specific T cells show the potential to be noninvasively imaged by classical X-ray computed tomography, which provides a convenient way to track immune cells in immunotherapy [235] . More interestingly, gold NPs can predict the therapeutic response to immune checkpoint blockade after modification with programmed death-ligand 1 antibody (αPD-L1) [236] . Gold-based NPs may also be combined with adjuvants to promote antitumor immune responses and contribute to cancer immunotherapy [237, 238] . Microneedles with dimensions of <1 mm can be utilized to pierce the skin to the dermis in a minimally invasive and painless manner [239] [240] [241] . As a significant research target, microneedles have been used in many aspects, such as the delivery of small molecule and protein drugs and vaccines [242] [243] [244] . It is an inexpensive and Advanced biomaterials for cancer immunotherapy F Yang et al. convenient way to use microneedles for various medical applications [245] [246] [247] [248] [249] . There are many lymph nodes in the dermis; thus, microneedles achieve direct contact with DCs for antigen uptake and presentation [27] . To decrease the cost of treatment and reduce the dosage-dependent side effect [250] [251] [252] of immunomodulators, Gu and coworkers prepared biocompatible hyaluronic acid (HA)-based microneedles integrated with pH-sensitive dextran NPs containing aPD1 and glucose oxidase, which realized the substantial release of aPD1 and evoked a strong immune response in B16F10-bearing mice [253] . Meanwhile, the same group designed another microneedle system that combined aPD1 and 1-methyl-DL-tryptophan (1-MT), an inhibitor of IDO, to promote T-cell immunity and reduce immunosuppression [254] . Moreover, a hyaluronic acid-based MN encapsulated B16F10 melanoma whole tumor lysate and GM-CSF were proven to stimulate a robust antitumor immune response through spatiotemporal PTT and immunotherapy (Fig. 7 ) [255] . In addition to soluble microneedles, hollow microneedles can also be used for vaccine delivery and immunotherapy on account of the controllability and accuracy of the injection progress [256, 257] . Researchers compared four types of NP-loaded OVA and poly(I:C) by using hollow microneedles, which showed that PLGA NPs and liposomes could provoke stronger IgG2a responses [258] . In addition, a digitally controlled hollow microneedle system was used for the injection of liposomes containing an HPV E 743-63 synthetic long peptide, thus reducing pain and the dosage of injection [259] . In recent years, biologically derived nanobiomaterials, such as cancer cell membranes, viral proteins, and DNAs, have started to be used for new cancer nanovaccines [260] [261] [262] [263] . Researchers found that tumor antigens and subcellular particles in the cancer membrane, such as melanoma cells, could be loaded into various NPs, which induce specific cellular and humoral responses, thus preventing tumor growth [157, 264, 265] . Another approach is to form virus-like NPs via the self-assembly of viral proteins [266] . Furthermore, cowpea mosaic virus NPs effectively evoked cytokine secretion and inhibited tumor growth in various models (Fig. 8) [267] . Reprinted with permission from [267] Advanced biomaterials for cancer immunotherapy F Yang et al. In this review, we have analyzed different strategies of immunotherapy and described advanced biomaterials that may be applied to improve therapeutic potency and reduce adverse effects. Although cancer immunotherapy is advancing at a high speed, the use of biomaterials to manufacture optimal systems for various tumors remains in its nascent stages. It is hoped that the biomaterials described in this review can be more widely and innovatively designed for cancer immunotherapy, thus promoting its efficacy and reducing immune-related side effects. Although preliminary advances have been made in the design of immunotherapy strategies based on biomaterials, many systems, including NPs, micelles, and hydrogels, can be loaded with multiple drugs and selected based on the targets identified in the patient's biopsy sample. This personalized treatment will be an important and promising research direction in the future. Treatment of hairy cell leukemia with recombinant alpha-interferon Delivery technologies for cancer immunotherapy Cell and fluid sampling microneedle patches for monitoring skin-resident immunity Macroscale biomaterials strategies for local immunomodulation Tailoring biomaterials for cancer immunotherapy: emerging trends and future outlook The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893 Immunity in response to particulate antigen-delivery systems Designing polymeric particles for antigen delivery Immune system targeting by biodegradable nanoparticles for cancer vaccines Effector and memory T-cell differentiation: implications for vaccine development The promise of cancer vaccines Interferon in the treatment of hairy-cell leukemia IL-2: the first effective immunotherapy for human cancer Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone Sipuleucel-T immunotherapy for castration-resistant prostate cancer Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy Improved survival with ipilimumab in patients with metastatic melanoma Engineered T cells: the promise and challenges of cancer immunotherapy Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia Delivering safer immunotherapies for cancer Is autoimmunity the Achilles' heel of cancer immunotherapy Advances in cancer immunotherapy in solid tumors Biopolymer implants enhance the efficacy of adoptive T-cell therapy The preparation of C-reactive protein immunosensor based on nano-mimetic enzyme Co 3 O 4 Recent progress of fully synthetic carbohydratebased vaccine using TLR agonist as build-in adjuvant Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy Designing hydrogels for controlled drug delivery Divergent immune responses to synthetic and biological scaffolds Effect of pore structure of macroporous poly (lactide-co-glycolide) scaffolds on the in vivo enrichment of dendritic cells Emerging opportunities and challenges in cancer immunotherapy Engineering challenges for brain tumor immunotherapy Eradication of spontaneous malignancy by local immunotherapy Immunosensors based on nanomaterials for detection of tumor markers Polymeric hydrogels for post-operative adhesion prevention: a review Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization Engineering nanoparticlecoated bacteria as oral DNA vaccines for cancer immunotherapy Tumor microenvironment responsive drug-dye-peptide nanoassembly for enhanced tumor-targeting, penetration, and photo-chemo-immunotherapy Viruses and interferon: a fight for supremacy Inhibition of tumor angiogenesis by interferon-gamma by suppression of tumor-associated macrophage differentiation Cytokines and the inception of CD8 T cell responses Interleukin-12 and the regulation of innate resistance and adaptive immunity Advanced biomaterials for cancer IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation Recent progress in GM-CSF-based cancer immunotherapy The blockade of immune checkpoints in cancer immunotherapy Immune suppressive mechanisms in the tumor microenvironment PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome Immune checkpoint inhibitors in cancer therapy Immune checkpoint inhibitors for patients with advanced non-small-cell lung cancer: a systematic review Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review Cancer immunotherapyimmune checkpoint blockade and associated endocrinopathies Acquired resistance to immunotherapy and future challenges Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors? T cell exclusion, immune privilege, and the tumor microenvironment The principles of engineering immune cells to treat cancer Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells Global manufacturing of CAR T cell therapy Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma Tisagenlecleucel in children and young Adults with B-cell lymphoblastic leukemia CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma Human CD26(high) T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia CAR T-Cell therapies in glioblastoma: a first look Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer High-throughput identification of antigen-specific TCRs by TCR gene capture Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma Therapeutic cancer vaccines: past, present, and future The cancer vaccine resurgence Cancer immunotherapy: moving beyond current vaccines Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells Whole tumor antigen vaccines: where are we? Vaccines Allogeneic tumor cell vaccines: the promise and limitations in clinical trials mRNA vaccines-a new era in vaccinology DNA vaccines: an historical perspective and view to the future DNA vaccine for cancer immunotherapy Developing mRNA-vaccine technologies Materials for non-viral intracellular delivery of messenger RNA therapeutics Preclinical and clinical development of neoantigen vaccines Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma Efficient nanovaccine delivery in cancer immunotherapy Functionalized multi-walled carbon nanotubes for targeting delivery of immunostimulatory CpG oligonucleotides against prostate cancer Local and systemic delivery of interleukin-12 gene by cationic micelles for cancer immunogene therapy Cancer immunotherapy via dendritic cells The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting Defining human dendritic cell progenitors by multiparametric flow cytometry Identification of cDC1-and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow Decisions about dendritic cells: past, present, and future Origin and development of dendritic cells Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow In situ dendritic cell vaccine for effective cancer immunotherapy Designing vaccines based on biology of human dendritic cell subsets Is there still room for cancer vaccines at the era of checkpoint inhibitors Dendritic cell-based immunotherapy Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells Cationic solid lipid nanoparticles as non viral vectors for the inhibition of hepatocellular carcinoma growth by RNA interference Recent advances with liposomes as pharmaceutical carriers Recent developments of liposomes as nanocarriers for theranostic applications New developments in liposomal drug delivery The enhanced antitumor-specific immune response with mannose-and CpG-ODN-coated liposomes delivering TRP2 peptide A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy Bioactive polysaccharidebased pH-sensitive polymers for cytoplasmic delivery of antigen and activation of antigen-specific immunity pH-sensitive polymer-liposome-based antigen delivery systems potentiated with interferongamma gene lipoplex for efficient cancer immunotherapy pH-sensitive polymer-modified liposome-based immunity-inducing system: effects of inclusion of cationic lipid and CpG-DNA Enhancing adoptive cell therapy of cancer through targeted delivery of small-molecule immunomodulators to internalizing or noninternalizing receptors Doxil(R)-the first FDA-approved nano-drug: lessons learned CTLA-4 blockade in tumor models: an overview of preclinical and translational research Immune checkpoint blockade in cancer therapy The safety and side effects of monoclonal antibodies Improved tumor accumulation and therapeutic efficacy of CTLA-4-blocking antibody using liposome-encapsulated antibody: In vitro and in vivo studies Modifying antigenencapsulating liposomes with KALA facilitates MHC class I antigen presentation and enhances anti-tumor effects Combinatorial photothermal and immuno cancer therapy using chitosan-coated hollow copper sulfide nanoparticles Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis An endogenous vaccine based on fluorophores and multivalent immunoadjuvants regulates tumor microenvironment for synergistic photothermal and immunotherapy Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response Preparation and biocompatibility evaluation of PEG-PLL/RGD-PEG-DSPE/Phospholipid/CaP nanoparticles Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer Necroptotic cancer cellsmimicry nanovaccine boosts anti-tumor immunity with tailored immunestimulatory modality Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes Redox-responsive supramolecular micelles for targeted imaging and drug delivery to tumor Effect of the poly(ethylene glycol) (PEG) density on the access and uptake of particles by antigen-presenting cells (APCs) after subcutaneous administration Exploiting lymphatic transport and complement activation in nanoparticle vaccines PEGylated cationic liposomes robustly augment vaccine-induced immune responses: role of lymphatic trafficking and biodistribution Viral capsids mimicking based on pH-sensitive biodegradable polymeric micelles for efficient anticancer drug delivery Cationic micelle delivery of Trp2 peptide for efficient lymphatic draining and enhanced cytotoxic Tlymphocyte responses A novel nitric oxide-based anticancer therapeutics by macrophage-targeted poly(l-arginine)-based nanoparticles ROS-inducing micelles sensitize tumor-associated macrophages to TLR3 stimulation for potent immunotherapy Enhanced apoptosis, survivin down-regulation and assisted immunochemotherapy by curcumin loaded amphiphilic mixed micelles for subjugating endometrial cancer Curcumin micelles remodel tumor microenvironment and enhance vaccine activity in an advanced melanoma model Development of a long-acting, protein-loaded, redox-active, injectable gel formed by a polyion complex for local protein therapeutics Feasibility of a subcutaneously administered block/homo-mixed polyplex micelle as a carrier for DNA vaccination in a mouse tumor model Rational design of polymeric hybrid micelles to overcome lymphatic and intracellular delivery barriers in cancer immunotherapy Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo Integrated nanovaccine with microRNA-148a inhibition reprograms tumor-associated dendritic cells by modulating miR-148a/DNMT1/SOCS1 axis Synthetic polymeric mixed micelles targeting lymph nodes trigger enhanced cellular and humoral immune responses Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations Biodegradation and biocompatibility of PLA and PLGA microspheres PLGA-based nanoparticles: an overview of biomedical applications Biodegradable polymeric nanoparticles based drug delivery systems Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo Delivery of a peptide via poly(D,L-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy Targeted PLGA nano-but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro Intradermal delivery of vaccine nanoparticles using hollow microneedle array generates enhanced and balanced immune response Acidic pHresponsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapy A novel human papillomavirus 16 L1 pentamer-loaded hybrid particles vaccine system: influence of size on immune responses Cancer cell membranecoated nanoparticles for anticancer vaccination and drug delivery Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma Erythrocyte membraneenveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice Chronic stress suppresses anti-tumor TCD8 + responses and tumor regression following cancer immunotherapy in a mouse model of melanoma Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy Immunomodulatory magnetic microspheres for augmenting tumor-specific infiltration of natural killer (NK) cells Nanovaccine incorporated with hydroxychloroquine enhances antigen cross-presentation and promotes antitumor immune responses CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses A dual immunotherapy nanoparticle improves T-cell activation and cancer immunotherapy Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy Sustained release of anti-PD-1 peptide for perdurable immunotherapy together with photothermal ablation against primary and distant tumors Laser immunotherapy in combination with perdurable PD-1 blocking for the treatment of metastatic tumors Combination of NIR therapy and regulatory T cell modulation using layer-by-layer hybrid nanoparticles for effective cancer photoimmunotherapy Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: a comparative study of cationic liposomes and PLGA nanoparticles Antigencapturing nanoparticles improve the abscopal effect and cancer immunotherapy Biomaterials for enhancing anti-cancer immunity Nanogel vaccines targeting dendritic cells: contributions of the surface decoration and vaccine cargo on cell targeting and activation Hydrogels and scaffolds for immunomodulation Anticancer supramolecular hydrogel of D/L-peptide with enhanced stability and bioactivity Self-assembly of succinated paclitaxel into supramolecular hydrogel for local cancer chemotherapy Self-assembled small molecular weight hydrogels of prodrugs Photosensitive peptide hydrogels as smart materials for applications Injectable dendritic cellcarrying alginate gels for immunization and immunotherapy In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice Nanogelbased immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity Growth inhibitory effect of an injectable hyaluronic acid-tyramine hydrogels incorporating human natural interferon-alpha and sorafenib on renal cell carcinoma cells Surgical tumor-derived personalized photothermal vaccine formulation for cancer immunotherapy Infection-mimicking materials to program dendritic cells in situ In situ regulation of DC subsets and T cells mediates tumor regression in mice Injectable cryogel-based whole-cell cancer vaccines Enzyme-catalyzed formation of supramolecular hydrogels as promising vaccine adjuvants A powerful CD8(+) T-cell stimulating D-tetra-peptide hydrogel as a very promising vaccine adjuvant Combined local immunostimulatory radioisotope therapy and systemic immune checkpoint blockade imparts potent antitumour responses In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment Designable immune therapeutical vaccine system based on DNA supramolecular hydrogels Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma A cancer vaccinemediated postoperative immunotherapy for recurrent and metastatic tumors Mesoporous silica nanoparticles in biomedical applications Morphology-controlled synthesis of mesoporous silica with co-template of surfactant P123 and ionic liquid Dmim Cl A novel electrochemiluminescence immunosensor for the analysis of HIV-1 p24 antigen based on P-RGO@Au@Ru-SiO 2 composite Dual pH and glucose sensitive gel gated mesoporous silica nanoparticles for drug delivery Biodegradable metal ion-doped mesoporous silica nanospheres stimulate anticancer Th1 immune response in vivo Precise manipulation of biophysical particle parameters enables control of proinflammatory cytokine production in presence of TLR 3 and 4 ligands Mesoporous silica particles induce size dependent effects on human dendritic cells Asymmetric silica nanoparticles with tunable head-tail structures enhance hemocompatibility and maturation of immune cells Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica to enhanced antitumor immunity Glutathione-depletion mesoporous organosilica nanoparticles as a self-adjuvant and Co-delivery platform for enhanced cancer immunotherapy Silica nanoparticle as a lymph node targeting platform for vaccine delivery Robust vaccine formulation produced by assembling a hybrid coating of polyethyleneimine-silica The enhanced immune response of hepatitis B virus DNA vaccine using SiO2@LDH nanoparticles as an adjuvant Nanostructured SBA-15 silica: an effective protective vehicle to oral hepatitis B vaccine immunization Hydrated silica exterior produced by biomimetic silicification confers viral vaccine heatresistance Viral inhibition mechanism mediated by surface-modified silica nanoparticles Engineered hydrogen-bonded glycopolymer capsules and their interactions with antigen presenting cells Engineering polymer hydrogel nanoparticles for lymph node-targeted delivery Hollow structure improved anti-cancer immunity of mesoporous silica nanospheres in vivo Mechanically tunable, self-adjuvanting nanoengineered polypeptide particles Physicochemical and immunological assessment of engineered pure protein particles with different redox states Multi-shelled dendritic mesoporous organosilica hollow spheres: roles of composition and architecture in cancer immunotherapy Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy The effect of surface modification of mesoporous silica micro-rod scaffold on immune cell activation and infiltration A facile approach to enhance antigen response for personalized cancer vaccination Long term in vivo biotransformation of iron oxide nanoparticles A review of clinical translation of inorganic nanoparticles Selenium and iron oxide nanocomposites for magnetically-targeted anti-cancer applications 70-kDa heat shock protein coated magnetic nanocarriers as a nanovaccine for induction of anti-tumor immune response in experimental glioma Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles Microdosed lipid-coated (67)Ga-magnetite enhances antigen-specific immunity by image tracked delivery of antigen and CpG to lymph nodes Magnetic enrichment of dendritic cell vaccine in lymph node with fluorescent-magnetic nanoparticles enhanced cancer immunotherapy Laser-photosensitizer assisted immunotherapy: a novel modality for cancer treatment Doxorubicin-loaded dextranmodified goldmag nanoparticles for targeting hepatocellular carcinoma JQ1-loaded polydopamine nanoplatform inhibit c-MYC/PD-L1 to enhance photothermal therapy for triple-negative breast cancer Biomimetic albuminmodified gold nanorods for photothermo-chemotherapy and macrophage polarization modulation Conjugating Prussian blue nanoparticles onto antigen-specific T cells as a combined nanoimmunotherapy Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma Imaging and selective elimination of glioblastoma stem cells with theranostic nearinfrared-labeled CD133-specific antibodies Nanomedicine for cancer immunotherapy: tracking cancer-specific T-cells in vivo with gold nanoparticles and CT imaging Fast imageguided stratification using anti-programmed death ligand 1 gold nanoparticles for cancer immunotherapy Nanoantagonists with nanophase-segregated surfaces for improved cancer immunotherapy DNA nanotechnology-based composite-type gold nanoparticle-immunostimulatory DNA hydrogel for tumor photothermal immunotherapy Infusion pressure and pain during microneedle injection into skin of human subjects Microneedle technologies for (trans) dermal drug and vaccine delivery Cutaneous microenvironment responsive microneedle patch for rapid gene release to treat subdermal tumor Microneedles for drug and vaccine delivery Dissolving microneedles for transdermal drug delivery: advances and challenges Microneedle, bio-microneedle and bio-inspired microneedle: a review Analgesic microneedle patch for neuropathic pain therapy Thrombin-responsive transcutaneous patch for auto-anticoagulant regulation Microneedles in the clinic Hypoxia and H 2 O 2 dualsensitive vesicles for enhanced glucose-responsive insulin delivery Enhanced cancer vaccination by in situ nanomicelle-generating dissolving microneedles Safety, activity, and immune correlates of anti-PD-1 antibody in cancer PEGylated antibodies and antibody fragments for improved therapy: a review Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody Synergistic transcutaneous immunotherapy enhances antitumor immune responses through delivery of checkpoint inhibitors A melanin-mediated cancer immunotherapy patch Advanced biomaterials for cancer Novel hollow microneedle technology for depth-controlled microinjectionmediated dermal vaccination: a study with polio vaccine in rats Determination of depth-dependent intradermal immunogenicity of adjuvanted inactivated polio vaccine delivered by microinjections via hollow microneedles Intradermal vaccination with hollow microneedles: a comparative study of various protein antigen and adjuvant encapsulated nanoparticles Hollow microneedle-mediated micro-injections of a liposomal HPV E743-63 synthetic long peptide vaccine for efficient induction of cytotoxic and T-helper responses Transient and local expression of chemokine and immune checkpoint traps to treat pancreatic cancer Design and development of nanosized DNA assemblies in polypod-like structures as efficient vehicles for immunostimulatory CpG motifs to immune cells Nanoparticle-based manipulation of antigenpresenting cells for cancer immunotherapy Eradication of established tumors by chemically self-assembled nanoring labeled T cells A membrane vesicle-based dual vaccine against melanoma and Lewis lung carcinoma Adjuvant-loaded subcellular vesicles derived from disrupted cancer cells for cancer vaccination In situ vaccination with cowpea vs tobacco mosaic virus against melanoma In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer The authors would like to thank the following funding sources: The National Science Competing interests: The authors declare no competing interests. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.